Get started
Author

Sarah Farooq

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
2019 · Panagiotis A Konstantinopoulos, William T Barry, et al. · The Lancet Oncology · 262
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
2016 · U.A. Matulonis, G.M. Wulf, et al. · Annals of Oncology · 219
PDF
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
2016 · Rachel A. Freedman, Rebecca S. Gelman, et al. · Journal of Clinical Oncology · 171
TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).
2017 · Rachel A. Freedman, Rebecca Sue Gelman, et al. · Journal of Clinical Oncology · 36
A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
2018 · Joyce F. Liu, William Thomas Barry, et al. · Journal of Clinical Oncology · 16
Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.
2017 · Joyce F. Liu, William Thomas Barry, et al. · Journal of Clinical Oncology · 14
Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer
2018 · U.A. Matulonis, W. Barry, et al. · Gynecologic Oncology · 9
Phase II, two-stage study of avelumab in patients with microsatellite stable (MSS), microsatellite instable (MSI) and polymerase epsilon (POLE) mutated recurrent or persistent endometrial cancer
2018 · P.A. Konstantinopoulos, J.F. Liu, et al. · Gynecologic Oncology · 7
Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and POLE-mutated recurrent or persistent endometrial cancer.
2017 · Panagiotis A. Konstantinopoulos, Joyce F. Liu, et al. · Journal of Clinical Oncology · 7
Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort
2017 · Panagiotis A. Konstantinopoulos, William T. Barry, et al. · Cancer Research · 5
Abstract OT3-2-05: Randomized phase II study of fulvestrant with or without ganetespib in patients (pts) with hormone receptor (HR)-positive metastatic breast cancer
2013 · NU Lin, L Whitesell, et al. · Cancer Research
Works count: 11
Citation count: 746
H-index: 7
I10-index: 6
Year
Topic
Type